Tag: Novo Nordisk
Next-Gen Obesity Drug Disappoints: Novo Nordisk Shares Drop
Novo Nordisk, a pharmaceutical giant, recently experienced a setback that sent shockwaves through the industry. The company's highly anticipated next-generation obesity drug, CagriSema, failed to meet investors' expectations, resulting in a significant drop in...
Critics question transparency as U.K. trade group lifts Novo Nordisk suspension
A U.K. trade group is preparing to lift a two-year suspension of Novo Nordisk due to "serious breaches" in promoting an obesity drug. The suspension, which was issued on March 16, 2023, by the...
